mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
about
CIViC databaseATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastomaGenetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapyGenome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathyThe maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes.Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancerClinical significance of ABCB1 genotyping in oncology.Taxane pathway.Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathwayRepositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Pharmacogenetics of analgesic drugsThe ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicityGenome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemiaUpdate on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.Pharmacogenetics and oncology treatment for breast cancer.Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesisPolymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.Pharmaco(epi)genomics in ovarian cancer.The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
P2860
Q27612411-03D30ECC-D5D4-4A45-9435-E5531ED4618DQ27851666-5166FF07-5AC7-4CD6-A5FC-2C160EF934F3Q27851688-520A380A-C5F7-464E-A236-15D762D04E59Q27851876-3E278E73-0C2C-4D86-9D33-F0857B603C7FQ28390726-4AA6DB5E-5ECC-46AD-9087-110F7430BB7CQ28536735-81682D8E-4214-4CBA-8432-0C0728F092C3Q28943314-421463AC-D282-40B4-BC0F-05DAC39381DDQ33388089-786F6B76-277B-4459-8BCE-82101E1D0816Q33418358-F6921365-BFF4-4DED-ADA1-AFB7575CA5ACQ33516216-618865B3-5ADB-4461-9446-DFC28CCEBA4FQ33586121-8112377F-D518-43C2-8166-743C0C1B8C41Q33951034-B6A703C3-8144-4FC3-AB88-0F66E710893BQ34390370-998E40E7-2189-42D3-9E7F-D6792543707AQ34673530-26A2C8EF-8923-49BB-AE0D-26F90A814B54Q34774854-BC7A64F1-2691-4394-BDEC-C5E18FA1EB4EQ35051318-C38778E1-99DC-40B7-A75B-38519DA53635Q35212672-8353E001-B42C-4DB8-B8C4-1D2B03D82D0DQ35243396-02FEE614-74D5-42E4-B6CF-C08396DE4AADQ35746647-91C1DB77-D7E1-4E1A-8AE1-4A06C6893DAFQ35837949-C3871B9C-4184-4F98-9A89-D6FAD7B7BE43Q36035404-26120086-9EA5-4C27-8BB6-9327CBF53986Q36043023-047ACC5F-B1C5-4335-8DEB-A1F1E027DA62Q36110592-E17A9EC7-AA1E-49C5-82ED-22C4C8F7B328Q36216741-3EF276AF-67BF-4CCD-98C5-881429502232Q36218993-1FB52C29-B771-4857-8AAA-1675CA54E96EQ36545157-46D41BFB-C208-473F-A7C2-F1F2EFDA8E25Q36605135-2B7DEF3D-F7AF-4A3E-BF97-1DF5B7724B1AQ36691820-6FDC946A-5F99-460C-B8A2-D1A3BC223213Q36719659-5C4732E0-8456-4D99-B01B-8DBCE7AE9DE1Q36724762-642E50AD-E17E-49B0-B5CA-B58248421F38Q36885663-9938222D-1B93-41FD-A115-29F54F8E3439Q37055326-5D6DFFD0-643E-4AD7-8D5F-56ABF5AE5AC5Q37186425-358A0135-6591-4E00-A295-2B7C4B02B6B4Q37187663-461C4F4F-87FA-4DB7-904D-23CF4F1CF65AQ37227494-DCCD8D98-4EB6-49BA-8F07-B7871E0FF987Q37297173-63E95B91-6807-4EC3-82BD-DED1DA0957F7Q37346198-9C5F96DB-A7F2-4429-9ECA-5B6EBB5F93D1Q37576360-6E2D8B34-0595-474E-82EC-0E9F1CFFAE0FQ37684533-50BA5F15-03A4-40E7-8A31-3AA5ED865C39Q37725978-C03B01B4-844A-4CDE-9447-A6BFBECB44A1
P2860
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@ast
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@en
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@nl
type
label
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@ast
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@en
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@nl
prefLabel
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@ast
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@en
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@nl
P2093
P921
P3181
P1476
mdr-1 single nucleotide polymo ...... se to paclitaxel chemotherapy.
@en
P2093
Curt Peterson
György Horvath
Henrik Gréen
Per Rosenberg
Peter Söderkvist
P3181
P356
10.1158/1078-0432.CCR-05-0950
P407
P433
P577
2006-02-01T00:00:00Z